<!DOCTYPE html>



<html lang="en">



	<meta charset="UTF-8">

	<meta name="viewport" content="width=device-width, initial-scale=1.0">

	<style>


    .node {

        stroke: #fff;

        stroke-width: 2px;

    }

    

    .link {

        stroke: #777;

        stroke-width: 2px;

    }



</style>

<body>

<a href="https://riskrunners.com">Home</a><br>




<a href="#risk_factors">Jump to Risk Factors</a><br>



<a href="#industry">Jump to Industries</a><br>


<a href="#exposure">Jump to Exposures</a><br>


<a href="#event_code">Jump to Event Codes</a><br>


<a href="#wiki">Jump to Wiki Summary</a><br><br>


    <script src="https://d3js.org/d3.v3.min.js"></script>

    <script>


// set a width and height for our SVG

var width = 3000,


    height = 3000;

    
// setup links

var links =     [
{source: "START_HERE", target: "1: regulatory requirements", fill: "#32127a"},
{source: "1: regulatory requirements", target: "1: necessary", fill: "#32127a"},
{source: "1: necessary", target: "1: will prevent us", fill: "#32127a"},
{source: "1: will prevent us", target: "1: partners from", fill: "#32127a"},
{source: "1: partners from", target: "1: commercializing", fill: "#32127a"},
{source: "1: regulatory requirements", target: "3: development", fill: "#b03060"},
{source: "3: development", target: "3: commercial use", fill: "#b03060"},
{source: "3: commercial use", target: "3: regulated by", fill: "#b03060"},
{source: "3: regulated by", target: "3: regulatory", fill: "#b03060"},
{source: "3: development", target: "9: clinical testing", fill: "#9370db"},
{source: "9: clinical testing", target: "9: regulatory approval", fill: "#9370db"},
{source: "9: regulatory approval", target: "9: products may", fill: "#9370db"},
{source: "9: products may", target: "9: expensive than", fill: "#9370db"},
{source: "9: expensive than", target: "9: which could", fill: "#9370db"},
{source: "9: which could", target: "9: financial condition", fill: "#9370db"},
{source: "9: financial condition", target: "9: operations", fill: "#9370db"},
{source: "9: clinical testing", target: "32: future capital requirements depend on", fill: "#f4bbff"},
{source: "32: future capital requirements depend on", target: "32: payments under", fill: "#f4bbff"},
{source: "32: payments under", target: "32: corporate partner agreements", fill: "#f4bbff"},
{source: "32: corporate partner agreements", target: "32: agreements", fill: "#f4bbff"},
{source: "32: agreements", target: "32: capital funding under", fill: "#f4bbff"},
{source: "32: capital funding under", target: "32: debt financing agreements", fill: "#f4bbff"},
{source: "32: debt financing agreements", target: "32: preclinical development clinical", fill: "#f4bbff"},
{source: "32: preclinical development clinical", target: "32: regulatory approvals", fill: "#f4bbff"},
{source: "32: regulatory approvals", target: "32: obligations", fill: "#f4bbff"},
{source: "32: obligations", target: "32: Collaboration and License Agreement ", fill: "#f4bbff"},
{source: "32: Collaboration and License Agreement ", target: "32: Schering AG ", fill: "#f4bbff"},
{source: "32: Schering AG ", target: "32: entering into new collaborative", fill: "#f4bbff"},
{source: "32: entering into new collaborative", target: "32: product license", fill: "#f4bbff"},
{source: "32: product license", target: "32: technology transfer associated with", fill: "#f4bbff"},
{source: "32: technology transfer associated with", target: "32: manufacturing", fill: "#f4bbff"},
{source: "32: manufacturing", target: "32: supply agreements", fill: "#f4bbff"},
{source: "32: future capital requirements depend on", target: "37: technologies", fill: "#ffff31"},
{source: "37: technologies", target: "37: development", fill: "#ffff31"},
{source: "37: development", target: "37: commercialization", fill: "#ffff31"},
{source: "37: commercialization", target: "37: proprietary", fill: "#ffff31"},
{source: "37: proprietary", target: "37: technology", fill: "#ffff31"},
{source: "37: technologies", target: "140: volatility may affect", fill: "#ffbf00"},
{source: "140: volatility may affect", target: "140: common stock may", fill: "#ffbf00"},
{source: "140: common stock may", target: "140: sudden decreases", fill: "#ffbf00"},
{source: "140: volatility may affect", target: "141: common stock", fill: "#c4c3d0"},
{source: "141: common stock", target: "START_HERE", fill: "#c4c3d0"}]; 
    // create empty nodes array
    var nodes = {};
	var colorFill = [];
	
    // compute nodes from links data
    links.forEach(function(link) {
        link.source = nodes[link.source] ||
            (nodes[link.source] = {name: link.source});
        link.target = nodes[link.target] ||
            (nodes[link.target] = {name: link.target});
		colorFill.push({name: link.source.name, fill: link.fill });
		colorFill.push({name: link.target.name, fill: link.fill });
    });
	
	console.log(colorFill);


    // add a SVG to the body for our viz
    var svg=d3.select('body').append('svg')
        .attr("viewBox", "0 0 " + width + " " + height );

    // use the force
    var force = d3.layout.force()
		.charge(-5000)
		.gravity(0.3)
        .size([width, height])
        .nodes(d3.values(nodes))
        .links(links)
        .on("tick", tick)
        .linkDistance(200)
        .start();

    // add links
    var link = svg.selectAll('.link')
        .data(links)
        .enter().append('line')
        .attr('class', 'link'); 

    // add nodes
    var node = svg.selectAll('.node')
        .data(force.nodes())
        .enter().append('circle')
        .attr('class', 'node')
        .attr('r', width * 0.0035)
		.style("fill", function(d) {
									for (var i = 0; i < colorFill.length; i++) {
										//console.log(d.name);
										if(colorFill[i].name == d.name){
											console.log(colorFill[i].fill);
											return colorFill[i].fill;
										}
									} return "#555";
									
									});
	var label = svg.selectAll(null)
		.data(force.nodes())
		.enter()
		.append("text")
		.text(function (d) { return d.name; })
		.style("text-anchor", "middle")
		.style("fill", "#555")
		.style("font-family", "Arial")
		.style("font-size", 34);


    // what to do 
    function tick(e) {
        
        node.attr('cx', function(d) { return d.x = Math.max(6, Math.min(width - 6, d.x)); })
            .attr('cy', function(d) { return d.y = Math.max(6, Math.min(height - 6, d.y)); })
            .call(force.drag);
            
        link.attr('x1', function(d) { return d.source.x; })
            .attr('y1', function(d) { return d.source.y; })
            .attr('x2', function(d) { return d.target.x; })
            .attr('y2', function(d) { return d.target.y; });
		
		label.attr("x", function(d){ return d.x; })
             .attr("y", function (d) {return d.y - 10; });
        
    }
    
</script><table border="1" class="dataframe">
  <thead>
    <tr style="text-align: right;">
      <th id='industry'>Industries</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td>Application Software</td>
    </tr>
    <tr>
      <td>Technology Hardware Storage and Peripherals</td>
    </tr>
    <tr>
      <td>Information Technology</td>
    </tr>
    <tr>
      <td>Technology Hardware and Equipment</td>
    </tr>
    <tr>
      <td>Health Care Distribution and Services</td>
    </tr>
    <tr>
      <td>Pharmaceuticals Biotechnology and Life Sciences</td>
    </tr>
    <tr>
      <td>Biotechnology</td>
    </tr>
    <tr>
      <td>Automobile Manufacturers</td>
    </tr>
    <tr>
      <td>Motorcycle Manufacturers</td>
    </tr>
    <tr>
      <td>Health Care Facilities</td>
    </tr>
    <tr>
      <td>Asset Management and Custody Banks</td>
    </tr>
    <tr>
      <td>Health Care Supplies</td>
    </tr>
    <tr>
      <td>Health Care</td>
    </tr>
    <tr>
      <td>Health Care Equipment and Services</td>
    </tr>
    <tr>
      <td>Managed Health Care</td>
    </tr>
    <tr>
      <td>Commercial and Professional Services</td>
    </tr>
    <tr>
      <td>Diversified Commercial Services</td>
    </tr>
  </tbody>
</table><table border="1" class="dataframe">
  <thead>
    <tr style="text-align: right;">
      <th id='exposure'>Exposures</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td>Military</td>
    </tr>
    <tr>
      <td>Ease</td>
    </tr>
    <tr>
      <td>Judicial</td>
    </tr>
    <tr>
      <td>Leadership</td>
    </tr>
    <tr>
      <td>Express intent</td>
    </tr>
    <tr>
      <td>Cooperate</td>
    </tr>
    <tr>
      <td>Regime</td>
    </tr>
    <tr>
      <td>Provide</td>
    </tr>
    <tr>
      <td>Economic</td>
    </tr>
  </tbody>
</table><table border="1" class="dataframe">
  <thead>
    <tr style="text-align: right;">
      <th id='event_code'>Event Codes</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td>Request</td>
    </tr>
    <tr>
      <td>Solicit support</td>
    </tr>
    <tr>
      <td>Complain</td>
    </tr>
    <tr>
      <td>Accident</td>
    </tr>
    <tr>
      <td>Sports contest</td>
    </tr>
    <tr>
      <td>Force</td>
    </tr>
    <tr>
      <td>Demand</td>
    </tr>
    <tr>
      <td>Adjust</td>
    </tr>
    <tr>
      <td>Reject</td>
    </tr>
    <tr>
      <td>Endorse</td>
    </tr>
    <tr>
      <td>Warn</td>
    </tr>
    <tr>
      <td>Yield</td>
    </tr>
    <tr>
      <td>Agree</td>
    </tr>
    <tr>
      <td>Sanction</td>
    </tr>
    <tr>
      <td>Yield position</td>
    </tr>
    <tr>
      <td>Yield to order</td>
    </tr>
    <tr>
      <td>Vote</td>
    </tr>
    <tr>
      <td>Human death</td>
    </tr>
    <tr>
      <td>Release or return</td>
    </tr>
    <tr>
      <td>Defy norms</td>
    </tr>
    <tr>
      <td>Acknowledge responsibility</td>
    </tr>
    <tr>
      <td>Decline comment</td>
    </tr>
    <tr>
      <td>Natural disaster</td>
    </tr>
  </tbody>
</table><table border="1" class="dataframe">
  <thead>
    <tr style="text-align: right;">
      <th id='wiki'>Wiki</th>
      <th>Wiki Summary</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Regulatory_affairs">Regulatory affairs</a></td>
      <td>Regulatory affairs (RA), also called government affairs, is a profession within regulated industries, such as pharmaceuticals, medical devices, cosmetics, agrochemicals (plant protection products and fertilizers), energy, banking, telecom etc.  Regulatory affairs also has a very specific meaning within the healthcare industries (pharmaceuticals, medical devices, biologics and functional foods).</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Sustainable_development">Sustainable development</a></td>
      <td>Sustainable development is an organizing principle for meeting human development goals while also sustaining the ability of natural systems to provide the natural resources and ecosystem services on which the economy and society depend. The desired result is a state of society where living conditions and resources are used to continue to meet human needs without undermining the integrity and stability of the natural system.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Research_and_development">Research and development</a></td>
      <td>Research and development (R&amp;D or R+D), known in Europe as research and technological development (RTD), is the set of innovative activities undertaken by corporations or governments in developing new services or products, and improving existing ones. Research and development constitutes the first stage of development of a potential new service or the production process.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Development_hell">Development hell</a></td>
      <td>Development hell, development purgatory, and development limbo are media and software industry jargon for a project, concept, or idea that remains in development for an especially long time, often moving between different crews, scripts, game engines, or studios before it progresses to production, if it ever does. Projects in development hell are usually not released until development has reached a satisfying state worthy of being released, ready for production.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Professional_development">Professional development</a></td>
      <td>Professional development is learning to earn or maintain professional credentials such as academic degrees to formal coursework, attending conferences, and informal learning opportunities situated in practice. It has been described as intensive and collaborative, ideally incorporating an evaluative stage.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Regulatory_state">Regulatory state</a></td>
      <td>The term regulatory state refers to the expansion in the use of rulemaking, monitoring and enforcement techniques and institutions by the state and to a parallel change in the way its positive or negative functions in society are being carried out. The expansion of the state nowadays is generally via regulation and less via taxing and spending.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Regulatory_capture">Regulatory capture</a></td>
      <td>In politics, regulatory capture (also agency capture and client politics) is a form of corruption of authority that occurs when a political entity, policymaker, or regulator is co-opted to serve the commercial, ideological, or political interests of a minor constituency, such as a particular geographic area, industry, profession, or ideological group.When regulatory capture occurs, a special interest is prioritized over the general interests of the public, leading to a net loss for society. The theory of client politics is related to that of rent-seeking and political failure; client politics "occurs when most or all of the benefits of a program go to some single, reasonably small interest (e.g., industry, profession, or locality) but most or all of the costs will be borne by a large number of people (for example, all taxpayers)".</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Regulatory_sequence">Regulatory sequence</a></td>
      <td>A regulatory sequence is a segment of a nucleic acid molecule which is capable of increasing or decreasing the expression of specific genes within an organism. Regulation of gene expression is an essential feature of all living organisms and viruses.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Regulatory_focus_theory">Regulatory focus theory</a></td>
      <td>Regulatory focus theory (RFT) is a theory of goal pursuit: 444  formulated by Columbia University psychology professor and researcher E. Tory Higgins regarding people's perceptions in the decision making process. RFT examines the relationship between the motivation of a person and the way in which they go about achieving their goal.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Gene_regulatory_network">Gene regulatory network</a></td>
      <td>A gene (or genetic) regulatory network (GRN) is a collection of molecular regulators that interact with each other and with other substances in the cell to govern the gene expression levels of mRNA and proteins which, in turn, determine the function of the cell. GRN also play a central role in morphogenesis, the creation of body structures, which in turn is central to evolutionary developmental biology (evo-devo).</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Operation_Mincemeat">Operation Mincemeat</a></td>
      <td>Operation Mincemeat was a successful British deception operation of the Second World War to disguise the 1943 Allied invasion of Sicily. Two members of British intelligence obtained the body of Glyndwr Michael, a tramp who died from eating rat poison, dressed him as an officer of the Royal Marines and placed personal items on him identifying him as the fictitious Captain (Acting Major) William Martin.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Arithmetic">Arithmetic</a></td>
      <td>Arithmetic (from Ancient Greek  ἀριθμός (arithmós) 'number', and  τική [τέχνη] (tikḗ [tékhnē]) 'art, craft') is an elementary part of mathematics that consists of the study of the properties of the traditional operations on numbers—addition, subtraction, multiplication, division, exponentiation, and extraction of roots. In the 19th century, Italian mathematician Giuseppe Peano formalized arithmetic with his Peano axioms, which are highly important to the field of mathematical logic today.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Operations_management">Operations management</a></td>
      <td>Operations management is an area of management concerned with designing and controlling the process of production and redesigning business operations in the production of goods or services. It involves the responsibility of ensuring that business operations are efficient in terms of using as few resources as needed and effective in meeting customer requirements.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Emergency_operations_center">Emergency operations center</a></td>
      <td>An emergency operations center (EOC) is a central command and control facility responsible for carrying out the principles of emergency preparedness and emergency management, or disaster management functions at a strategic level during an emergency, and ensuring the continuity of operation of a company, political subdivision or other organization.\nAn EOC is responsible for strategic direction and operational decisions and does not normally directly control field assets, instead leaving tactical decisions to lower commands.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Operations_research">Operations research</a></td>
      <td>Operations research (British English: operational research), often shortened to the initialism OR, is a discipline that deals with the development and application of advanced analytical methods to improve decision-making. It is sometimes considered to be a subfield of mathematical sciences.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Operation_Condor">Operation Condor</a></td>
      <td>Operation Condor (Spanish: Operación Cóndor, also known as Plan Cóndor; Portuguese: Operação Condor) was a United States-backed campaign of political repression and state terror involving intelligence operations and assassination of opponents. It was officially and formally implemented in November 1975 by the right-wing dictatorships of the Southern Cone of South America.Due to its clandestine nature, the precise number of deaths directly attributable to Operation Condor is highly disputed.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Technology">Technology</a></td>
      <td>Technology is the result of accumulated knowledge and application of skills, methods, and processes used in industrial production and scientific research. Technology is embedded in the operation of all machines, with or without detailed knowledge of their function, for the intended purpose of an organization.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Manufacturing_engineering">Manufacturing engineering</a></td>
      <td>Manufacturing engineering is a branch of professional engineering that shares many common concepts and ideas with other fields of engineering such as mechanical, chemical, electrical, and industrial engineering. \nManufacturing engineering requires the ability to plan the practices of manufacturing; to research and to develop tools, processes, machines and equipment; and to integrate the facilities and systems for producing quality products with the optimum expenditure of capital.The manufacturing or production engineer's primary focus is to turn raw material into an updated or new product in the most effective, efficient &amp; economic way possible.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Manufacturing_cost">Manufacturing cost</a></td>
      <td>Manufacturing cost is the sum of costs of all resources consumed in the process of making a product. The manufacturing cost is classified into three categories: direct materials cost, direct labor cost and manufacturing overhead.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Murata_Manufacturing">Murata Manufacturing</a></td>
      <td>Murata Manufacturing Co., Ltd. (株式会社村田製作所, Kabushiki-gaisha Murata Seisakusho) is a Japanese manufacturer of electronic components, based in Nagaokakyo, Kyoto.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Information_technology">Information technology</a></td>
      <td>Information technology (IT) is the use of computers to create, process, store, retrieve, and exchange all kinds of electronic data and information. IT is typically used within the context of business operations as opposed to personal or entertainment technologies.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Technology_company">Technology company</a></td>
      <td>A technology company (or tech company) is an electronics-based technological company, including, for example, business relating to digital electronics, software, and internet-related services, such as e-commerce services.\n\n\n== Details ==\nAccording to Fortune, as of 2020, the ten largest technology companies by revenue are: Apple Inc., Samsung, Foxconn, Alphabet Inc., Microsoft, Huawei, Dell Technologies, Hitachi, IBM, and Sony.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Financial_technology">Financial technology</a></td>
      <td>Financial technology (abbreviated fintech or FinTech) is the technology and innovation that aims to compete with traditional financial methods in the delivery of financial services. Artificial intelligence, Blockchain, Cloud computing, and big Data are regarded as the "ABCD" (four key areas) of FinTech.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Educational_technology">Educational technology</a></td>
      <td>Educational technology (commonly abbreviated as edutech, or edtech) is the combined use of computer hardware, software, and educational theory and practice to facilitate learning. When referred to with its abbreviation, edtech, it is often referring to the industry of companies that create educational technology.In addition to practical educational experience, educational technology is based on theoretical knowledge from various disciplines such as communication, education, psychology, sociology, artificial intelligence, and computer science.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Language_technology">Language technology</a></td>
      <td>Language technology, often called human language technology (HLT), studies methods of how computer programs or electronic devices can analyze, produce, modify or respond to human texts and speech. Working with language technology often requires broad knowledge not only about linguistics but also about computer science.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Space_technology">Space technology</a></td>
      <td>Space technology is technology for use in outer space, in travel (astronautics) or other activities beyond Earth's atmosphere, for purposes such as spaceflight, space exploration, and Earth observation. Space technology includes space vehicles such as spacecraft, satellites, space stations and orbital launch vehicles; deep-space communication; in-space propulsion; and a wide variety of other technologies including support infrastructure equipment, and procedures.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Bachelor_of_Technology">Bachelor of Technology</a></td>
      <td>A Bachelor of Technology (Latin Baccalaureus Technologiae, commonly abbreviated as B.Tech. or BTech; with honours as B.Tech.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Common_stock">Common stock</a></td>
      <td>Common stock is a form of corporate equity ownership, a type of security. The terms voting share and ordinary share are also used frequently outside of the United States.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Common_stock_dividend">Common stock dividend</a></td>
      <td>A common stock dividend is the dividend paid to common stock owners from the profits of the company.  Like other dividends, the payout is in the form of either cash or stock.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Preferred_stock">Preferred stock</a></td>
      <td>Preferred stock (also called preferred shares, preference shares, or simply preferreds) is a component of share capital that may have any combination of features not possessed by common stock, including properties of both an equity and a debt instrument, and is generally considered a hybrid instrument. Preferred stocks are senior (i.e., higher ranking) to common stock but subordinate to bonds in terms of claim (or rights to their share of the assets of the company, given that such assets are payable to the returnee stock bond) and may have priority over common stock (ordinary shares) in the payment of dividends and upon liquidation.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Matthiola_incana">Matthiola incana</a></td>
      <td>Matthiola incana is a species of flowering plant in the cabbage family Brassicaceae. Common names include Brompton stock, common stock, hoary stock, ten-week stock, and gilly-flower.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Consolidation_(business)">Consolidation (business)</a></td>
      <td>In business, consolidation or amalgamation is the merger and acquisition of many smaller companies into a few much larger ones. In the context of financial accounting, consolidation refers to the aggregation of financial statements of a group company as consolidated financial statements.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/New_York_Stock_Exchange">New York Stock Exchange</a></td>
      <td>The New York Stock Exchange (NYSE, nicknamed "The Big Board") is an American stock exchange in the Financial District of Lower Manhattan in New York City. It is by far the world's largest stock exchange by market capitalization of its listed companies at US$30.1 trillion as of February 2018.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Convertible_bond">Convertible bond</a></td>
      <td>In finance, a convertible bond or  convertible note or convertible debt (or a convertible debenture if it has a maturity of greater than 10 years) is a type of bond that the holder can convert into a specified number of shares of common stock in the issuing company or cash of equal value.  It is a hybrid security with debt- and equity-like features.</td>
    </tr>
  </tbody>
</table><table border="1" class="dataframe">
  <thead>
    <tr style="text-align: right;">
      <th id='risk_factors'>Risk Factors</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td>SONUS PHARMACEUTICALS INC   ITEM 1A RISK FACTORS         Governmental <font color="blue"><font color="blue">regulatory</font> <font color="blue">requirements</font></font> are lengthy and expensive and failure     to  obtain  <font color="blue">necessary</font>  approvals  <font color="blue">will prevent us</font> or our <font color="blue">partners from</font>     <font color="blue">commercializing</font> a product</td>
    </tr>
    <tr>
      <td>We are subject to uncertain <font color="blue">government</font>al <font color="blue"><font color="blue">regulatory</font> <font color="blue">requirements</font></font> and a     <font color="blue">lengthy approval process</font> for our products prior to any <font color="blue">commercial sales</font> of     our  products</td>
    </tr>
    <tr>
      <td>The <font color="blue">development</font> and <font color="blue">commercial use</font> of our products are     <font color="blue">regulated by</font> the US Food and Drug Administration, or FDA, the European     Medicines Evaluation Agency, or EMEA, and comparable <font color="blue">regulatory</font> agencies in     other countries</td>
    </tr>
    <tr>
      <td>The <font color="blue">regulatory</font> approval process for <font color="blue">new products</font> is lengthy     and expensive</td>
    </tr>
    <tr>
      <td>Before we can submit an <font color="blue">application</font> to the FDA and comparable     <font color="blue">international</font>  agencies,  the product candidate must undergo extensive     testing, including animal studies and human <font color="blue">clinical trial</font>s that can take     many years and require substantial <font color="blue">expenditures</font></td>
    </tr>
    <tr>
      <td>Data obtained from such     <font color="blue">testing may</font> be susceptible to varying interpretations, <font color="blue">which could</font> delay,     limit or prevent <font color="blue">regulatory</font> approval</td>
    </tr>
    <tr>
      <td>In addition, changes in <font color="blue">regulatory</font>     policy for <font color="blue">product approval may</font> cause <font color="blue"><font color="blue">additional</font> costs</font> in our efforts to     secure <font color="blue">necessary</font> approvals</td>
    </tr>
    <tr>
      <td>Our <font color="blue">product <font color="blue">candidates</font></font> are subject to <font color="blue"><font color="blue">significant</font> uncertainty</font> because they     are  in  both  early  to <font color="blue">late stages</font> of <font color="blue">development</font> and are subject to     <font color="blue">regulatory</font> approval</td>
    </tr>
    <tr>
      <td>The results of preclinical and <font color="blue">clinical testing</font> of our     products are uncertain and <font color="blue">regulatory</font> approval of our <font color="blue">products may</font> take     longer or be more <font color="blue">expensive than</font> anticipated, <font color="blue">which could</font> have a material     adverse  effect  on  our  business, <font color="blue">financial condition</font> and results of     <font color="blue">operations</font></td>
    </tr>
    <tr>
      <td>The FDA has indicated to Sonus that NDA     approval under 505(b)(2) will require either (i) <font color="blue">demonstration</font> of superior     efficacy of TOCOSOL Paclitaxel as compared to Taxol; or (ii) <font color="blue">demonstration</font>     of non-inferior efficacy of TOCOSOL Paclitaxel as compared to Taxol, and     either a change of the <font color="blue">approved label</font> for Taxol and generic <font color="blue">equivalents</font> to     include a <font color="blue">weekly dosing</font> schedule or <font color="blue">availability</font> of reviewable data from a     Phase  3  trial  comparing the efficacy of Taxol using a <font color="blue">weekly dosing</font>     schedule to that of Taxol using the currently approved three-<font color="blue">weekly dosing</font>     schedule</td>
    </tr>
    <tr>
      <td>12     ______________________________________________________________________         We do not currently believe that the timing or cost <font color="blue">of the Phase </font>3 trial or     the NDA <font color="blue">submission will</font> be <font color="blue"><font color="blue">adversely</font> affected by</font> these <font color="blue">requirements</font></td>
    </tr>
    <tr>
      <td>The     <font color="blue">clinical trial</font> <font color="blue">Protocol and Statistical Analysis Plan </font><font color="blue">approved under</font> the SPA     provide  for  sequential  superiority analyses for efficacy of TOCOSOL     Paclitaxel  compared  to  Taxol,  provided that we <font color="blue">first <font color="blue">demonstrate</font></font> a     non-inferior <font color="blue">objective response rate</font>; however, there can be no assurance     that  the  Phase  3  <font color="blue">clinical trial</font> data will <font color="blue">demonstrate</font> that TOCOSOL     Paclitaxel has efficacy that is non-inferior or superior to Taxol</td>
    </tr>
    <tr>
      <td>Further,     there can be no assurance that the <font color="blue">approved label</font> for Taxol or generics will     be changed to provide for <font color="blue">weekly dosing</font>, although we do believe, based on     repeated <font color="blue">discussions</font> with the FDA, that they are pursuing this change</td>
    </tr>
    <tr>
      <td>Large     Phase 3 <font color="blue">clinical trial</font>s have been conducted by <font color="blue">third parties</font>, utilizing     Taxol on a <font color="blue">weekly versus</font> a three-weekly basis, and data from those studies     may be available for submission to the FDA in support of our NDA However,     there can be no assurance that Sonus will have right of reference to the     <font color="blue">data from such trials</font></td>
    </tr>
    <tr>
      <td>If Sonus is required to conduct an <font color="blue">additional</font> Phase 3     trial of Taxol given <font color="blue">weekly versus</font> three-weekly, substantial <font color="blue">additional</font>     costs and time would be required before the NDA submission for TOCOSOL     Paclitaxel</td>
    </tr>
    <tr>
      <td>In  addition,  there  is <font color="blue">pending <font color="blue">litigation</font> attacking</font> the     <font color="blue">utilization</font> of the 505(b)(2) <font color="blue">regulatory</font> strategy generally</td>
    </tr>
    <tr>
      <td>There can be no     assurance   that   such   <font color="blue">litigation</font>   will   not   be  successful</td>
    </tr>
    <tr>
      <td>A     505(b)(2) <font color="blue">application</font> permits us to rely upon the FDA’s findings of safety     and efficacy for a <font color="blue">previously approved drug product without</font> requiring us to     obtain a right of <font color="blue">reference from</font> the <font color="blue">original applicant</font></td>
    </tr>
    <tr>
      <td>In addition to     permitting  reliance  upon  the  FDA’s  prior  findings  of safety and     <font color="blue"><font color="blue">effective</font>ness</font> for <font color="blue">previously approved drugs</font>, section 505(b)(2) continues to     <font color="blue">allow reliance on third party data</font> that is available in <font color="blue">published literature</font>     and <font color="blue">which establishes</font> the safety and <font color="blue"><font color="blue">effective</font>ness</font> of a drug</td>
    </tr>
    <tr>
      <td>However, we     are  required  to  provide  any  <font color="blue">additional</font> clinical data <font color="blue">necessary</font> to     <font color="blue">demonstrate</font> the safety and <font color="blue"><font color="blue">effective</font>ness</font> of <font color="blue">differences between</font> the original     drug and the 505(b)(2) drug, so while un<font color="blue">necessary</font> duplication of preclinical     and <font color="blue">certain human studies</font> is avoided, specific studies may be required to     establish  the  relevance  and <font color="blue">applicability</font> of <font color="blue">prior findings</font> for our     <font color="blue">particular product formulation</font></td>
    </tr>
    <tr>
      <td>We <font color="blue">cannot predict</font> if or when any of our     <font color="blue">products under</font> <font color="blue">development</font> will be <font color="blue"><font color="blue">commercialize</font>d</font></td>
    </tr>
    <tr>
      <td>We will need <font color="blue">additional</font> capital in the future, and if it is not <font color="blue">available on</font>     terms  acceptable  to  us,  or at all, we would have to scale back our     <font color="blue">expenditures</font> and our <font color="blue">development</font> and <font color="blue"><font color="blue">commercialization</font> <font color="blue">activities</font></font></td>
    </tr>
    <tr>
      <td>We expect that our cash <font color="blue">requirements</font> <font color="blue">will continue</font> to increase in future     <font color="blue">periods due</font> to <font color="blue">development</font> costs associated with TOCOSOL Paclitaxel and     other <font color="blue">product <font color="blue">candidates</font></font></td>
    </tr>
    <tr>
      <td>We estimate that existing cash, cash <font color="blue">equivalents</font>     and <font color="blue">marketable securities</font>, in addition to <font color="blue">payments pending</font> and <font color="blue">cost sharing</font>     <font color="blue"><font color="blue">arrangements</font> under</font> our <font color="blue">Collaboration and <font color="blue">License Agreement </font></font>with Schering AG,     will be sufficient to fund <font color="blue">operations</font> through at least the end of the first     quarter of 2007</td>
    </tr>
    <tr>
      <td>We will need <font color="blue">additional</font> capital to complete the <font color="blue">development</font>     of TOCOSOL Paclitaxel, fund our <font color="blue"><font color="blue">obligations</font> under</font> the <font color="blue">collaborative license</font>     <font color="blue"><font color="blue">agreement</font> with</font> Schering, fund the <font color="blue">development</font> of other <font color="blue">product <font color="blue">candidates</font></font>     and support our continuing <font color="blue">operations</font></td>
    </tr>
    <tr>
      <td>In addition to the <font color="blue">supportive trials</font>     Sonus plans to conduct, it is anticipated that we <font color="blue">will collaborate with</font>     Schering on <font color="blue">additional</font> studies</td>
    </tr>
    <tr>
      <td>Under the terms of the Collaboration and     <font color="blue">License Agreement </font>with Schering, we are <font color="blue">also obligated</font> to fund 50prca of the     costs of <font color="blue">certain studies conducted by</font> <font color="blue">Schering for the US The </font>exact cost     and timing of these studies is yet to be finalized</td>
    </tr>
    <tr>
      <td>Our current estimate for     the <font color="blue">total cost</font> <font color="blue">of the Phase </font>3 trial is between dlra45 million and dlra50 million</td>
    </tr>
    <tr>
      <td>However, the scope, timing and costs <font color="blue">of the Phase </font>3 <font color="blue">clinical trial</font> are     <font color="blue">difficult</font> to determine <font color="blue">with accuracy</font> and these <font color="blue">costs may <font color="blue">vary <font color="blue">significant</font>ly</font></font>     depending upon <font color="blue">regulatory</font> and other matters that are not within our control</td>
    </tr>
    <tr>
      <td>Should our <font color="blue">clinical data support</font> an NDA <font color="blue">submission based on</font> the primary     endpoint of <font color="blue">objective response rate</font>, we anticipate that the NDA could be     submitted within 12 months after <font color="blue">conclusion</font> of <font color="blue">patient enrollment</font></td>
    </tr>
    <tr>
      <td>Our     future capital <font color="blue">requirements</font> depend on many factors including:         •                   our ability to obtain and timing of <font color="blue">payments under</font>     <font color="blue">corporate partner <font color="blue"><font color="blue">agreement</font>s</font></font>;       •                  our ability to obtain and timing of <font color="blue">capital funding under</font>     equity or <font color="blue">debt financing</font> <font color="blue"><font color="blue">agreement</font>s</font>;       •                  timing and costs of preclinical <font color="blue">development</font>, clinical     trials and <font color="blue">regulatory</font> approvals;       •                  timing and amount of costs to support our <font color="blue">obligations</font>     under the <font color="blue">Collaboration and <font color="blue">License Agreement </font></font>with Schering AG;       •                   <font color="blue">entering into new collaborative</font> or <font color="blue">product license</font>     <font color="blue"><font color="blue">agreement</font>s</font>;       •                  timing and costs of <font color="blue"><font color="blue">technology</font> transfer associated with</font>     <font color="blue">manufacturing</font> and supply <font color="blue"><font color="blue">agreement</font>s</font>; and       •                  costs related to obtaining, defending and enforcing     patents</td>
    </tr>
    <tr>
      <td>13     ______________________________________________________________________         Any <font color="blue">future debt</font> or <font color="blue">equity financing</font>, if available, may result in substantial     dilution  to  <font color="blue">existing stockholders</font>, and <font color="blue">debt financing</font>, if available,     may include <font color="blue">restrictive covenants</font></td>
    </tr>
    <tr>
      <td>If we are unable to raise <font color="blue">additional</font>     <font color="blue">financing by</font> the end of the <font color="blue">first quarter</font> of 2007, we will have to reduce     our <font color="blue">expenditures</font> and scale back the <font color="blue">development</font> of our products and new     <font color="blue">product research</font> and <font color="blue">development</font></td>
    </tr>
    <tr>
      <td>In addition, we may not be able to fund     our <font color="blue"><font color="blue">obligations</font> under</font> the <font color="blue">Collaboration and <font color="blue">License Agreement </font></font>with Schering,     in which case we could be in default under the <font color="blue">agreement</font> <font color="blue">which could</font> cause     us to incur penalties or the <font color="blue">agreement</font> to be terminated</td>
    </tr>
    <tr>
      <td>If we fail to develop <font color="blue">new products</font>, then we may never realize <font color="blue">revenue from</font>     <font color="blue">product <font color="blue">commercialization</font></font></td>
    </tr>
    <tr>
      <td>A key element of our business strategy is to utilize our <font color="blue">technologies</font> for     the  <font color="blue">development</font>  and  <font color="blue">commercialization</font>  of products that utilize our     <font color="blue">proprietary</font> TOCOSOL <font color="blue">technology</font></td>
    </tr>
    <tr>
      <td>Most of our attention and resources are     directed  to  the <font color="blue">development</font> of our <font color="blue">proprietary</font> TOCOSOL <font color="blue">technology</font>, a     <font color="blue">technology</font>  that provides a <font color="blue">novel approach</font> to the formulation of water     <font color="blue">insoluble compounds</font> for therapeutic <font color="blue">application</font>s</td>
    </tr>
    <tr>
      <td><font color="blue">Significant </font><font color="blue">expenditures</font>     in  <font color="blue">additional</font> research and <font color="blue">development</font>, <font color="blue">clinical testing</font>, <font color="blue">regulatory</font>,     <font color="blue">manufacturing</font>, and sales and <font color="blue">marketing <font color="blue">activities</font> will</font> be <font color="blue">necessary</font> in order     for us to <font color="blue">demonstrate</font> the efficacy of our products, or <font color="blue">commercialize</font> any     products developed with our <font color="blue">technology</font></td>
    </tr>
    <tr>
      <td>There can be no assurance that     <font color="blue">product <font color="blue">candidates</font></font> under <font color="blue">development</font> or any <font color="blue"><font color="blue">future products</font> will</font> be safe or     <font color="blue">efficacious</font></td>
    </tr>
    <tr>
      <td>If the <font color="blue">product <font color="blue">candidates</font></font> under <font color="blue">development</font> are ultimately     in<font color="blue">effective</font> in treating cancer, do not receive the <font color="blue">necessary</font> <font color="blue">regulatory</font>     approvals or do not obtain commercial <font color="blue">acceptance</font>, we will incur <font color="blue">additional</font>     losses, our <font color="blue">accumulated</font> deficit will increase and our business will be     <font color="blue">materially</font> <font color="blue">adversely</font> affected</td>
    </tr>
    <tr>
      <td>Even if we are successful in developing our products, there is no assurance     that <font color="blue">such products will</font> receive <font color="blue">regulatory</font> approval or that a <font color="blue">commercially</font>     <font color="blue">viable market will</font> develop</td>
    </tr>
    <tr>
      <td>We have a history of operating <font color="blue">losses which</font> we expect <font color="blue">will continue</font> and we     <font color="blue">may never <font color="blue">become profitable</font></font></td>
    </tr>
    <tr>
      <td>We have experienced <font color="blue">significant</font> <font color="blue">accumulated</font> losses since our inception, and     are expected to <font color="blue">incur net losses</font> for the <font color="blue">foreseeable future</font></td>
    </tr>
    <tr>
      <td>These losses     have resulted <font color="blue">primarily from expenses associated with</font> our research and     <font color="blue">development</font> <font color="blue">activities</font>, including nonclinical and <font color="blue">clinical trial</font>s, and     general  and  <font color="blue">administrative</font>  expenses</td>
    </tr>
    <tr>
      <td>We anticipate that our operating     losses <font color="blue">will continue</font> as we <font color="blue">further invest</font> in research and <font color="blue">development</font> for     our products</td>
    </tr>
    <tr>
      <td>We will not generate the majority of milestone or royalty     <font color="blue">revenues under</font> our <font color="blue">collaboration</font> and license <font color="blue"><font color="blue">agreement</font> with</font> <font color="blue">Schering AG     </font>unless and until we receive <font color="blue">regulatory</font> approvals, which are not likely to     occur until 2008 and beyond</td>
    </tr>
    <tr>
      <td>Even if we <font color="blue">generate milestone</font> and royalty     revenues, there can be no assurance that we will be able to achieve or     sustain  <font color="blue">profitability</font></td>
    </tr>
    <tr>
      <td>Our results of <font color="blue">operations</font> have varied and will     continue to <font color="blue">vary <font color="blue">significant</font>ly</font> and depend on, among other factors:         •                  timing of payments, under our Collaboration and License     Agreement with Schering or our ability to obtain other corporate partner     <font color="blue"><font color="blue">agreement</font>s</font> or other financing;       •                  timing and costs of preclinical <font color="blue">development</font>, clinical     trials and <font color="blue">regulatory</font> approvals;       •                  timing and amount of costs to support our <font color="blue">obligations</font>     under the <font color="blue">Collaboration and <font color="blue">License Agreement </font></font>with Schering;       •                  <font color="blue">drug <font color="blue">discovery</font></font> and research and <font color="blue">development</font>;       •                  timing and costs of <font color="blue"><font color="blue">technology</font> transfer associated with</font>     <font color="blue">manufacturing</font> and supply <font color="blue"><font color="blue">agreement</font>s</font>; and       •                  costs related to obtaining, defending and enforcing     patents</td>
    </tr>
    <tr>
      <td>We <font color="blue">depend on third</font>  parties for funding, clinical <font color="blue">development</font>, <font color="blue">manufacturing</font>     and <font color="blue">distribution</font> of TOCOSOL Paclitaxel</td>
    </tr>
    <tr>
      <td>We are <font color="blue">dependent</font>, and may in the future be <font color="blue">dependent</font>, on <font color="blue">third parties</font> for     funding or performance of a variety of <font color="blue">key <font color="blue">activities</font></font> including research,     clinical <font color="blue">development</font>, <font color="blue">manufacturing</font>, marketing, sales and <font color="blue">distribution</font> of     our products</td>
    </tr>
    <tr>
      <td>Our current business strategy is to enter into <font color="blue"><font color="blue">agreement</font>s</font> with     third  <font color="blue">parties both</font> to <font color="blue">license rights</font> to our <font color="blue">potential products</font> and to     develop  and <font color="blue">commercialize</font> <font color="blue">new products</font></td>
    </tr>
    <tr>
      <td>We executed an <font color="blue"><font color="blue">agreement</font> with</font>     Schering AG for TOCOSOL Paclitaxel in October 2005</td>
    </tr>
    <tr>
      <td>Under the Collaboration     and License Agreement,                                           14     ______________________________________________________________________                                                 Schering has a <font color="blue">worldwide exclusive license</font> to market and promote TOCOSOL     Paclitaxel  and is responsible for clinical <font color="blue">development</font> and <font color="blue">regulatory</font>     <font color="blue">activities</font> outside of the US If these <font color="blue"><font color="blue">arrangements</font> with</font> Schering or other     <font color="blue">third parties</font> are terminated or the <font color="blue">collaboration</font>s are not successful, we     will be required to identify <font color="blue"><font color="blue">alternative</font> sources</font> of funding to finance     research, clinical <font color="blue">development</font>, <font color="blue">manufacturing</font>, marketing, sales and/or     <font color="blue">distribution</font></td>
    </tr>
    <tr>
      <td>Our <font color="blue">inability</font> to secure <font color="blue">additional</font> funding would have a     material adverse effect on our business, <font color="blue">financial condition</font> and results of     <font color="blue">operations</font></td>
    </tr>
    <tr>
      <td>Our <font color="blue">success depends</font> in part upon the <font color="blue">performance by</font> these     <font color="blue">collaborators</font> of their <font color="blue">responsibilities under</font> these <font color="blue">arrangements</font></td>
    </tr>
    <tr>
      <td>We have no     <font color="blue">control over</font> the resources that our <font color="blue">partners may devote</font> to the <font color="blue">development</font>     and  <font color="blue">commercialization</font>  of <font color="blue">products under</font> these <font color="blue">collaboration</font>s and our     <font color="blue">partners may fail</font> to conduct their collaborative <font color="blue">activities</font> successfully or     in a <font color="blue">timely manner</font></td>
    </tr>
    <tr>
      <td>If we lose our <font color="blue">key personnel</font> or are unable to attract and retain qualified     scientific and <font color="blue"><font color="blue">management</font> personnel</font>, we may be unable to <font color="blue">become profitable</font></td>
    </tr>
    <tr>
      <td>We are highly <font color="blue">dependent</font> on our <font color="blue">key executives</font>, including Michael A Martino,     President &amp;  Chief  Executive Officer, Michael B Stewart, Senior Vice     President &amp; Chief Medical Officer and Alan Fuhrman, Senior Vice President &amp;     Chief Financial Officer</td>
    </tr>
    <tr>
      <td>We do not have employment <font color="blue"><font color="blue">agreement</font>s</font> in place with     these  <font color="blue">key executives</font> nor do we maintain any key person <font color="blue">life insurance</font>     <font color="blue">coverage on</font> these persons</td>
    </tr>
    <tr>
      <td>The loss of any of these <font color="blue">key executives</font> or the     <font color="blue">inability</font>  to  recruit  and  retain  <font color="blue">qualified scientific personnel</font> to     perform research and <font color="blue">development</font> and qualified <font color="blue"><font color="blue">management</font> personnel</font> could     have a material adverse effect on our business, <font color="blue">financial condition</font> and     results of <font color="blue">operations</font></td>
    </tr>
    <tr>
      <td>There can be no assurance that we will be able to     attract and retain <font color="blue">such personnel on</font> acceptable terms, if at all, given the     <font color="blue">competition</font> for experienced <font color="blue">scientists</font> and other <font color="blue">personnel among numerous</font>     medical   and  <font color="blue">pharmaceutical</font>  companies,  <font color="blue">universities</font>  and  research     <font color="blue">institutions</font></td>
    </tr>
    <tr>
      <td><font color="blue">Future US </font>or <font color="blue">international</font> <font color="blue">legislative</font> or <font color="blue">administrative</font> actions also     could prevent or delay <font color="blue">regulatory</font> approval of our products</td>
    </tr>
    <tr>
      <td>Even if <font color="blue">regulatory</font> approvals are obtained, they may include <font color="blue">significant</font>     <font color="blue">limitations on</font> the <font color="blue">indicated uses</font> for which a <font color="blue">product may</font> be marketed</td>
    </tr>
    <tr>
      <td>A     <font color="blue">marketed product also</font> is subject to continual FDA, EMEA and other <font color="blue">regulatory</font>     <font color="blue">agency review</font> and regulation</td>
    </tr>
    <tr>
      <td>Later <font color="blue">discovery</font> of <font color="blue">previously unknown problems</font>     or failure to <font color="blue">comply with</font> the applicable <font color="blue"><font color="blue">regulatory</font> <font color="blue">requirements</font></font> may result     in <font color="blue">restrictions on</font> the marketing of a product or withdrawal of the product     from  the  market, as well as possible civil or <font color="blue">criminal sanctions</font></td>
    </tr>
    <tr>
      <td>In     addition,  if  marketing  approval is obtained, the FDA, EMEA or other     <font color="blue">regulatory</font>  <font color="blue">agency may</font> require post-marketing testing and surveillance     programs to monitor the product’s efficacy and side effects</td>
    </tr>
    <tr>
      <td>Results of     these post-marketing programs may prevent or limit the further marketing of     a product</td>
    </tr>
    <tr>
      <td>The <font color="blue">development</font> of <font color="blue">pharmaceutical</font> products in general and the <font color="blue">development</font> of     <font color="blue">paclitaxel</font> <font color="blue">reformulations</font> in particular is <font color="blue">extremely competitive</font>, and if we     fail to <font color="blue">compete <font color="blue">effective</font>ly</font>, it <font color="blue">would negatively impact</font> our business</td>
    </tr>
    <tr>
      <td><font color="blue">Competition </font>in the <font color="blue">development</font> of <font color="blue">pharmaceutical</font> products is intense and     expected to increase</td>
    </tr>
    <tr>
      <td>We also believe that other medical and <font color="blue">pharmaceutical</font>     <font color="blue"><font color="blue">companies will</font> compete with us</font> in the areas of research and <font color="blue">development</font>,     <font color="blue">acquisition</font> of products and <font color="blue">technology</font> licenses, and the <font color="blue">manufacturing</font> and     marketing of our products</td>
    </tr>
    <tr>
      <td>Success of products in these fields will be based     primarily on:         •                  efficacy;       •                  safety;       •                  price;       •                  ease of <font color="blue">administration</font>;       •                  breadth of approved <font color="blue">indications</font>; and       •                  physician, healthcare payor and patient <font color="blue">acceptance</font></td>
    </tr>
    <tr>
      <td>Several other companies are developing <font color="blue">paclitaxel</font> <font color="blue">reformulations</font> with a goal     of delivering a more <font color="blue">effective</font> and tolerable therapy than the approved     <font color="blue">paclitaxel</font> products</td>
    </tr>
    <tr>
      <td>Some of these products are further in <font color="blue">development</font> than     TOCOSOL Paclitaxel and may achieve <font color="blue">regulatory</font> approval before our product</td>
    </tr>
    <tr>
      <td><font color="blue">On January </font>7, 2005, <font color="blue">American Pharmaceutical Partners </font>obtained FDA approval     to market its <font color="blue">paclitaxel</font>-based product, ABRAXANE (<font color="blue">paclitaxel</font> protein-bound     particles for <font color="blue">injectible suspension</font>)</td>
    </tr>
    <tr>
      <td>In addition, Sanofi-aventis has a     <font color="blue">taxane product</font>,                                           15     ______________________________________________________________________         Taxotere (docetaxel), which is similar to <font color="blue">paclitaxel</font> and is marketed for the     treatment of breast, non-small cell lung and <font color="blue">prostate cancers</font></td>
    </tr>
    <tr>
      <td>There are     also a number of generic <font color="blue">paclitaxel</font> products, identical to Taxol, currently     on the market</td>
    </tr>
    <tr>
      <td>As a result of the increased <font color="blue">competition</font>, the price for     <font color="blue">paclitaxel</font> products has <font color="blue">been under pressure</font> and may drop <font color="blue">significant</font>ly even     if we achieve <font color="blue">regulatory</font> approval</td>
    </tr>
    <tr>
      <td>Many  of  our  <font color="blue">competitors</font>  and potential <font color="blue">competitors</font>, including large     <font color="blue">pharmaceutical</font>, chemical and bio<font color="blue">technology</font> concerns and <font color="blue">universities</font> and     other research <font color="blue">institutions</font>, have <font color="blue">substantially</font> greater financial, technical     and human resources than we do and have <font color="blue">substantially</font> greater experience in     developing  products, obtaining <font color="blue">regulatory</font> approvals and marketing and     <font color="blue">manufacturing</font> medical products</td>
    </tr>
    <tr>
      <td>Accordingly, these <font color="blue">competitors</font> may succeed     in obtaining FDA approval for their products more <font color="blue">rapidly than</font> we do</td>
    </tr>
    <tr>
      <td>In     addition, other <font color="blue">technologies</font> or <font color="blue">products may</font> be developed that have an     <font color="blue">entirely different approach</font> that would render our <font color="blue">technology</font> and products     <font color="blue">noncompetitive</font> or obsolete</td>
    </tr>
    <tr>
      <td>If we fail to <font color="blue">compete <font color="blue">effective</font>ly</font>, it would have     a material adverse effect on our business, <font color="blue">financial condition</font> and results     of <font color="blue">operations</font></td>
    </tr>
    <tr>
      <td>We <font color="blue">rely on third party suppliers</font> and <font color="blue"><font color="blue">manufacture</font>rs</font> to produce products that     we develop and failure to retain <font color="blue">such suppliers</font> and <font color="blue"><font color="blue">manufacture</font>rs</font> would     <font color="blue">adversely</font> impact our ability to <font color="blue">commercialize</font> our products</td>
    </tr>
    <tr>
      <td>We  currently rely on <font color="blue">third parties</font> to supply the <font color="blue">chemical ingredients</font>     <font color="blue">necessary</font> for our drug <font color="blue">product <font color="blue">candidates</font></font></td>
    </tr>
    <tr>
      <td>We have <font color="blue">entered into supply</font>     <font color="blue"><font color="blue">agreement</font>s</font> for the supply of GMP grade <font color="blue">paclitaxel</font>, which is the active     <font color="blue">pharmaceutical</font> ingredient in TOCOSOL Paclitaxel</td>
    </tr>
    <tr>
      <td>The <font color="blue">chemical ingredients</font>     for  our products are <font color="blue"><font color="blue">manufacture</font>d by</font> a limited number of vendors</td>
    </tr>
    <tr>
      <td>The     <font color="blue">inability</font> of these vendors to supply medical-grade materials to us could     delay the <font color="blue">manufacturing</font> of, or cause us to cease the <font color="blue">manufacturing</font> of our     products</td>
    </tr>
    <tr>
      <td>We also rely on <font color="blue">third parties</font> to <font color="blue">manufacture</font> our products for     research and <font color="blue">development</font> and <font color="blue">clinical trial</font>s</td>
    </tr>
    <tr>
      <td>TEVA Pharmaceuticals USA     (TEVA)  is our primary <font color="blue">manufacture</font>r of TOCOSOL Paclitaxel for clinical     studies  and  has  also  agreed  to <font color="blue">manufacture</font> TOCOSOL Paclitaxel for     <font color="blue">commercialization</font></td>
    </tr>
    <tr>
      <td>The TEVA <font color="blue">agreement</font> has an <font color="blue">initial term</font> of <font color="blue">five years</font>     after  market <font color="blue">introduction</font> of TOCOSOL Paclitaxel, provided that market     <font color="blue">introduction</font> occurs before June 2009, and is not <font color="blue">terminable at will</font></td>
    </tr>
    <tr>
      <td>We     previously <font color="blue">manufacture</font>d clinical supplies of TOCOSOL Paclitaxel at other GMP     <font color="blue">certified contract laboratories</font></td>
    </tr>
    <tr>
      <td><font color="blue">Suppliers </font>and <font color="blue"><font color="blue">manufacture</font>rs</font> of our products     must operate under GMP <font color="blue">regulations</font>, as required by the FDA, and there are a     limited number of contract <font color="blue"><font color="blue">manufacture</font>rs</font> that operate under GMP <font color="blue">regulations</font></td>
    </tr>
    <tr>
      <td>GMP  are  enumerated  in  FDA  <font color="blue">regulations</font> and <font color="blue">guidance documents</font></td>
    </tr>
    <tr>
      <td>The     <font color="blue">facilities</font>, procedures, and <font color="blue">operations</font> of our contract <font color="blue"><font color="blue">manufacture</font>rs</font> must be     determined  to  be  adequate  by  the  FDA  before approval of product     <font color="blue">manufacturing</font></td>
    </tr>
    <tr>
      <td><font color="blue">Manufacturing </font><font color="blue">facilities</font> are subject to <font color="blue">inspections by</font> the     FDA  for  compliance with GMP, <font color="blue">licensing <font color="blue">specifications</font></font>, and other FDA     <font color="blue">regulations</font></td>
    </tr>
    <tr>
      <td>Failure to <font color="blue">comply with</font> FDA and other <font color="blue">government</font>al <font color="blue">regulations</font>     can  result in fines, unanticipated compliance <font color="blue">expenditures</font>, recall or     seizure  of products, total or <font color="blue">partial suspension</font> of production and/or     <font color="blue">distribution</font>,  suspension of the FDA’s review of NDAs, <font color="blue">injunctions</font> and     <font color="blue">criminal prosecution</font></td>
    </tr>
    <tr>
      <td>Our reliance on in<font color="blue">dependent</font> <font color="blue"><font color="blue">manufacture</font>rs</font> involves a number of     other risks, including the absence of <font color="blue">adequate capacity</font>, the un<font color="blue">availability</font>     of, or <font color="blue">interruptions</font> in, access to <font color="blue">necessary</font> <font color="blue">manufacturing</font> processes and     reduced <font color="blue">control over</font> delivery schedules</td>
    </tr>
    <tr>
      <td>If our <font color="blue"><font color="blue">manufacture</font>rs</font> are unable or     unwilling to continue <font color="blue">manufacturing</font> our products in required volumes or have     problems with commercial scale-up, we will have to identify acceptable     <font color="blue">alternative</font>  <font color="blue"><font color="blue">manufacture</font>rs</font></td>
    </tr>
    <tr>
      <td>The  use  of a new <font color="blue">manufacture</font>r may cause     <font color="blue">significant</font> <font color="blue">interruptions</font> in supply if the new <font color="blue">manufacture</font>r has <font color="blue">difficult</font>y     <font color="blue">manufacturing</font> products to our <font color="blue">specifications</font></td>
    </tr>
    <tr>
      <td>Further, the <font color="blue">introduction</font> of a     new <font color="blue">manufacture</font>r may increase the variation in the quality of our products</td>
    </tr>
    <tr>
      <td>If we fail to <font color="blue">secure adequate intellectual property protection</font> or become     involved in an <font color="blue">intellectual property dispute</font>, it could <font color="blue">significant</font>ly harm     our financial results and ability to compete</td>
    </tr>
    <tr>
      <td>Our  <font color="blue">success will depend</font>, in part, on our ability to obtain and defend     patents and <font color="blue">protect trade secrets</font></td>
    </tr>
    <tr>
      <td><font color="blue">As of December </font>31, 2005, we held seven     <font color="blue"><font color="blue">United States</font> </font>patents and <font color="blue">four patents outside</font> the US, one each in Canada,     Taiwan, Mexico and India pertaining to our <font color="blue">proprietary</font> TOCOSOL <font color="blue">technology</font></td>
    </tr>
    <tr>
      <td>We hold one <font color="blue">additional</font> <font color="blue"><font color="blue">United States</font> </font><font color="blue">patent directed</font> to other <font color="blue">technologies</font></td>
    </tr>
    <tr>
      <td><font color="blue">Additional  </font>patent  <font color="blue">application</font>s  are pending in the <font color="blue"><font color="blue">United States</font> </font>and     <font color="blue">counterpart</font> filings have been made in Europe, Canada and key countries in     <font color="blue">Asia and Latin America</font></td>
    </tr>
    <tr>
      <td>The <font color="blue">patent position</font> of medical and <font color="blue">pharmaceutical</font>     companies  is  <font color="blue">highly uncertain</font> and <font color="blue">involves complex legal</font> and factual     questions</td>
    </tr>
    <tr>
      <td>There can be no assurance that any claims which are included in     pending  or future patent <font color="blue">application</font>s will be issued, that any issued     patents  will  provide  us  <font color="blue">with competitive advantages</font> or will not be     <font color="blue">challenged by</font>                                           16     ______________________________________________________________________         <font color="blue">third parties</font>, or that the existing or <font color="blue">future patents</font> of <font color="blue">third parties</font> will     not have an adverse effect on our ability to <font color="blue">commercialize</font> our products</td>
    </tr>
    <tr>
      <td>Furthermore,  there  can be no assurance that other <font color="blue">companies will</font> not     in<font color="blue">dependent</font>ly develop similar products, duplicate any of our products or     <font color="blue">design around patents</font> that may be issued to us</td>
    </tr>
    <tr>
      <td><font color="blue">Litigation </font>may be <font color="blue">necessary</font>     to enforce any <font color="blue">patents issued</font> to us or to determine the scope and validity     of others’ <font color="blue">proprietary</font> rights in court or <font color="blue">administrative</font> <font color="blue">proceedings</font></td>
    </tr>
    <tr>
      <td>Any     <font color="blue">litigation</font> or <font color="blue">administrative</font> <font color="blue">proceeding could</font> result in substantial costs to     us and <font color="blue">distraction</font> of our <font color="blue">management</font></td>
    </tr>
    <tr>
      <td>An adverse ruling in any <font color="blue">litigation</font> or     <font color="blue">administrative</font>  <font color="blue">proceeding could</font> have a material adverse effect on our     business, <font color="blue">financial condition</font> and results of <font color="blue">operations</font></td>
    </tr>
    <tr>
      <td>Our commercial <font color="blue">success will depend</font> in part on not infringing <font color="blue">patents issued</font>     to <font color="blue">competitors</font></td>
    </tr>
    <tr>
      <td>There can be no assurance that <font color="blue">patents belonging</font> to <font color="blue">competitors</font> will not     require us to alter our products or processes, pay licensing fees or cease     <font color="blue">development</font> of our current or <font color="blue">future products</font></td>
    </tr>
    <tr>
      <td>Any <font color="blue">litigation</font> regarding     <font color="blue">infringement could</font> result in substantial costs to us and <font color="blue">distraction</font> of our     <font color="blue">management</font>, and any adverse ruling in any <font color="blue">litigation</font> could have a material     adverse  effect  on  our  business, <font color="blue">financial condition</font> and results of     <font color="blue">operations</font></td>
    </tr>
    <tr>
      <td>Further, there can be no assurance that we will be able to     license other <font color="blue">technology</font> that we may require at a <font color="blue">reasonable cost</font> or at all</td>
    </tr>
    <tr>
      <td>Failure by us to obtain a license to any <font color="blue">technology</font> that we may require to     <font color="blue">commercialize</font>  our  products  could  result  in the <font color="blue">termination</font> of the     <font color="blue">Collaboration and <font color="blue">License Agreement </font></font>with Schering and would have a material     adverse  effect  on  our  business, <font color="blue">financial condition</font> and results of     <font color="blue">operations</font></td>
    </tr>
    <tr>
      <td>In addition, to determine the priority of <font color="blue">inventions</font> and the     <font color="blue">ultimate ownership</font> of patents, we <font color="blue">may participate</font> in interference, reissue     or re-examination <font color="blue">proceedings</font> conducted by the US Patent and Trademark     Office or in <font color="blue">proceedings</font> before <font color="blue">international</font> agencies with respect to any     of our existing patents or patent <font color="blue">application</font>s or any <font color="blue">future patents</font> or     <font color="blue">application</font>s, any of <font color="blue">which could</font> result in loss of ownership of existing,     <font color="blue">issued patents</font>, substantial costs to us and <font color="blue">distraction</font> of our <font color="blue">management</font></td>
    </tr>
    <tr>
      <td><font color="blue">Reimbursement </font>procedures and <font color="blue">future healthcare reform measures</font> are uncertain     and may <font color="blue">adversely</font> impact our ability to <font color="blue">successfully sell</font> <font color="blue">pharmaceutical</font>     products</td>
    </tr>
    <tr>
      <td>Our ability to <font color="blue">successfully sell</font> any <font color="blue">pharmaceutical</font> products will depend in     part on the extent to which <font color="blue">government</font> health <font color="blue">administration</font> authorities,     <font color="blue">private health insurers</font> and other <font color="blue">organizations will reimburse patients</font> for     the costs of future <font color="blue">pharmaceutical</font> products and related <font color="blue">treatments</font></td>
    </tr>
    <tr>
      <td>In the     United  States, <font color="blue">government</font> and other third-party payors have sought to     contain  healthcare  costs  <font color="blue">by limiting both coverage</font> and the level of     <font color="blue">reimbursement</font> for new <font color="blue">pharmaceutical</font> products approved for <font color="blue">marketing by</font> the     FDA In some cases, these <font color="blue">payors may refuse</font> to provide any coverage for uses     of <font color="blue">approved products</font> to <font color="blue">treat medical conditions even though</font> the FDA has     granted  <font color="blue">marketing approval</font></td>
    </tr>
    <tr>
      <td><font color="blue">Healthcare </font><font color="blue">reform may increase</font> these cost     <font color="blue">containment efforts</font></td>
    </tr>
    <tr>
      <td>We believe that <font color="blue">managed care organizations may seek</font> to     restrict the use of <font color="blue">new products</font>, delay authorization to use <font color="blue">new products</font> or     limit  coverage  and  the  level  of  <font color="blue">reimbursement</font>  for <font color="blue">new products</font></td>
    </tr>
    <tr>
      <td>Internationally, where <font color="blue">national healthcare systems</font> are prevalent, little if     any <font color="blue">funding may</font> be available for <font color="blue">new products</font>, and cost containment and cost     <font color="blue">reduction efforts</font> can be more pronounced than in the <font color="blue">United States</font></td>
    </tr>
    <tr>
      <td>If our products are not <font color="blue">accepted by</font> the <font color="blue">medical community</font> our business will     suffer</td>
    </tr>
    <tr>
      <td><font color="blue">Commercial </font>sales of our proposed products will <font color="blue">substantially</font> depend upon the     products’  efficacy  and on their <font color="blue">acceptance</font> by the <font color="blue">medical community</font></td>
    </tr>
    <tr>
      <td><font color="blue">Widespread </font><font color="blue">acceptance</font> of our products will require educating the medical     <font color="blue">community as</font> to the benefits and <font color="blue">reliability</font> of the products</td>
    </tr>
    <tr>
      <td>Our proposed     products  may not be accepted, and, even if accepted, we are unable to     estimate the length of time it would take to gain such <font color="blue">acceptance</font></td>
    </tr>
    <tr>
      <td>The businesses in which we engage have a risk of <font color="blue">product liability</font>, and in     the event of a <font color="blue">successful suit against us</font>, our business could be severely     harmed</td>
    </tr>
    <tr>
      <td>The testing, marketing and sale of <font color="blue">pharmaceutical</font> products entails a risk of     <font color="blue">product liability</font> claims <font color="blue">by consumers</font> and others</td>
    </tr>
    <tr>
      <td>We currently maintain     <font color="blue">product liability</font> insurance for our <font color="blue">clinical trial</font>s with limits of dlra10     <font color="blue">million per</font> claim and in the aggregate, which we believe to be adequate for     current non-commercial and Phase 3 <font color="blue">application</font>s of our products</td>
    </tr>
    <tr>
      <td>In the     event  of  a  <font color="blue">successful suit against us</font>, the lack or <font color="blue">insufficiency</font> of     insurance coverage could have a material adverse effect on our business and     <font color="blue">financial condition</font></td>
    </tr>
    <tr>
      <td>17     ______________________________________________________________________         Since we <font color="blue">use hazardous materials</font> in our business, we may be subject to     claims  relating  to  improper  handling, storage or disposal of these     materials</td>
    </tr>
    <tr>
      <td>Our  research and <font color="blue">development</font> <font color="blue">activities</font> involve the <font color="blue">controlled use</font> of     hazardous materials, chemicals and <font color="blue">various radioactive compounds</font></td>
    </tr>
    <tr>
      <td>We are     subject to federal, state and <font color="blue">local laws</font> and <font color="blue">regulations</font> governing the use,     <font color="blue">manufacture</font>, storage, handling and disposal of <font color="blue">such materials</font> and certain     <font color="blue">waste products</font></td>
    </tr>
    <tr>
      <td>Although we believe that our <font color="blue">safety procedures</font> for handling     and disposing of <font color="blue">such materials</font> <font color="blue">comply with</font> the <font color="blue">standards prescribed by</font>     state and federal <font color="blue">regulations</font>, the risk of <font color="blue"><font color="blue">accident</font>al contamination</font> or     <font color="blue">injury from</font> these <font color="blue">materials cannot</font> be <font color="blue">eliminated completely</font></td>
    </tr>
    <tr>
      <td>In the event of     such an <font color="blue">accident</font>, we could be held liable for any damages that result and     any <font color="blue">such liability</font> not <font color="blue">covered by insurance could exceed</font> our resources</td>
    </tr>
    <tr>
      <td><font color="blue">Compliance </font><font color="blue">with environmental laws</font> and <font color="blue">regulations</font> may be expensive, and     current  or  future environmental <font color="blue">regulations</font> may impair our research,     <font color="blue">development</font> or <font color="blue">production efforts</font></td>
    </tr>
    <tr>
      <td>Market <font color="blue">volatility may affect</font> our stock price and the value of an investment     in our <font color="blue"><font color="blue">common stock</font> may</font> be subject to <font color="blue">sudden decreases</font></td>
    </tr>
    <tr>
      <td>The  trading  price for our <font color="blue">common stock</font> has been, and we expect it to     continue to be, volatile</td>
    </tr>
    <tr>
      <td>The <font color="blue">price at which</font> our <font color="blue">common stock</font> trades depends     upon a number of factors, including our historical and anticipated operating     results, preclinical and <font color="blue">clinical trial</font> results, market perception of the     prospects for bio<font color="blue">technology</font> companies as an industry sector and general     market  and <font color="blue">economic conditions</font>, some of which are beyond our control</td>
    </tr>
    <tr>
      <td>Factors <font color="blue">such as fluctuations</font> in our financial and operating results, changes     in <font color="blue">government</font> <font color="blue">regulations</font> affecting product approvals, <font color="blue">reimbursement</font> or     other aspects of our or our <font color="blue">competitors</font>’ businesses, FDA review of our     product <font color="blue">development</font> <font color="blue">activities</font>, the results of <font color="blue">preclinical studies</font> and     clinical  trials,  <font color="blue">announcements</font>  of  <font color="blue">technological innovations</font> or new     <font color="blue">commercial products by us</font> or our <font color="blue">competitors</font>, <font color="blue">development</font>s concerning key     personnel and our intellectual property rights, <font color="blue">significant</font> <font color="blue">collaboration</font>s     or  strategic  alliances  and  publicity regarding actual or potential     performance of <font color="blue">products under</font> <font color="blue">development</font> by us or our <font color="blue">competitors</font> could     also cause the <font color="blue">market price</font> of our <font color="blue">common stock</font> to fluctuate <font color="blue">substantially</font></td>
    </tr>
    <tr>
      <td>In addition, the <font color="blue">stock market</font> has from time to time experienced extreme     price and <font color="blue">volume fluctuations</font></td>
    </tr>
    <tr>
      <td>These <font color="blue">broad market fluctuations may lower</font> the     <font color="blue">market price</font> of our <font color="blue">common stock</font></td>
    </tr>
    <tr>
      <td>Moreover, <font color="blue">during periods</font> of <font color="blue">stock market</font>     <font color="blue">price volatility</font>, share prices of many bio<font color="blue">technology</font> companies have often     fluctuated in a manner not <font color="blue">necessarily</font> related to the companies’ operating     performance</td>
    </tr>
    <tr>
      <td>Also, bio<font color="blue">technology</font> or <font color="blue">pharmaceutical</font> stocks may be volatile     even <font color="blue">during periods</font> of <font color="blue">relative market stability</font></td>
    </tr>
    <tr>
      <td>Accordingly, our common     stock may be subject to greater <font color="blue">price volatility</font> than the <font color="blue">stock market</font> as a     whole</td>
    </tr>
    <tr>
      <td>Failure to satisfy <font color="blue">Nasdaq National Market Listing </font><font color="blue">requirements</font> may result in     our <font color="blue">common stock</font> being <font color="blue">delisted from</font> <font color="blue">The Nasdaq National Market</font></td>
    </tr>
    <tr>
      <td>Our <font color="blue">common stock</font> is <font color="blue">currently listed on</font> <font color="blue">The Nasdaq National Market</font> under the     symbol “SNUS”  For <font color="blue">continued inclusion on</font> <font color="blue">The Nasdaq National Market</font>, we     must maintain among other <font color="blue">requirements</font> stockholders’ equity of at least     dlra10dtta0 million, a <font color="blue">minimum bid price</font> of dlra1dtta00 per share and a <font color="blue">market value</font> of     our <font color="blue">public float</font> of at least dlra5dtta0 million; or <font color="blue">market capitalization</font> of at     least dlra50 million, a <font color="blue">minimum bid price</font> of dlra1dtta00 per share and a <font color="blue">market value</font>     of our <font color="blue">public float</font> of at least dlra15dtta0 million</td>
    </tr>
    <tr>
      <td><font color="blue">As of December </font>31, 2005, we     had stockholders’ equity of approximately dlra35dtta3 million</td>
    </tr>
    <tr>
      <td>In the event that     we fail to satisfy the listing standards on a <font color="blue">continuous</font> basis, our common     stock may be removed from listing on <font color="blue">The Nasdaq National Market</font></td>
    </tr>
    <tr>
      <td>If our     <font color="blue">common stock</font> were <font color="blue">delisted from</font> <font color="blue">The Nasdaq National Market</font>, our <font color="blue">common stock</font>     may be transferred to the <font color="blue">Nasdaq SmallCap Market </font>if we satisfy the listing     criteria for the <font color="blue">Nasdaq SmallCap Market </font>or trading of our <font color="blue">common stock</font>, if     any, may be conducted in the over-the-counter market in the so-called “pink     sheets” or, if available, the National Association of Securities Dealer’s     “Electronic Bulletin Board</td>
    </tr>
    <tr>
      <td>”  In addition, delisting from Nasdaq may subject     our  <font color="blue">common stock</font> to so-called “penny stock” rules</td>
    </tr>
    <tr>
      <td>These <font color="blue">rules impose</font>     <font color="blue">additional</font> sales practice and market making <font color="blue">requirements</font> on broker-dealers     who  sell  and/or  make  a  market  in  <font color="blue">such securities</font></td>
    </tr>
    <tr>
      <td>Consequently,     broker-dealers may be <font color="blue">less willing</font> or able to sell and/or make a market in     our <font color="blue">common stock</font></td>
    </tr>
    <tr>
      <td>Additionally, an investor would find it more <font color="blue">difficult</font> to     dispose of, or to obtain accurate quotations for the price of, our common     stock</td>
    </tr>
    <tr>
      <td>As a result of a delisting, it may become more <font color="blue">difficult</font> for us to     <font color="blue">raise funds through</font> the sale of our securities</td>
    </tr>
  </tbody>
</table>